combination therapy of an anti-cd20 type ii antibody with an anti-bcl-2 active agent

摘要

The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.